Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1412 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Pharavee Jaiprasart und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Pharmacometrics, Janssen Research & Development, North Wales, PA, USA. Hauptthemen laut MEDLINE: Drug Interactions, Healthy Volunteers, Carbamazepine, Area Under Curve. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Erdafitinib, a selective and potent oral pan‐FGFR inhibitor, is metabolized mainly through CYP2C9 and CYP3A4 enzymes. This phase 1, open‐label, single‐sequence, drug‐drug interaction study evaluated the pharmacokinetics, safety, and tolerability of a single oral dose of erdafitinib alone and when co‐administered with steady state oral carbamazepine, a dual inducer of CYP3A4 and CYP2C9, in 13 healthy adult participants (NCT04330248). Compared with erdafitinib administration alone, carbamazepine co‐administration decreased total and free maximum plasma concentrations of erdafitinib (C max ) by 35% (95% CI 30%‐39%) and 22% (95% CI 17%‐27%), respectively. The areas under the concentration‐time curve over the time interval from 0 to 168 hours, to the last quantifiable data point, and to time infinity (AUC 168h , AUC last , AUC inf ), were markedly decreased for both total erdafitinib (56%‐62%) and free erdafitinib (48%‐55%). The safety profile of erdafitinib was consistent with previous clinical studies in healthy participants, with no new safety concerns when administered with or without carbamazepine. Co‐administration with carbamazepine may reduce the activity of erdafitinib due to reduced exposure. Concomitant use of strong CYP3A4 inducers with erdafitinib should be avoided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology & Pharmacometrics, Janssen Research & Development, North Wales, PA, USA.
- Oncology Research & Development, Janssen Research & Development, Beerse, Belgium.
- Statistics and Decision Science, Janssen Research & Development, Raritan, NJ, USA.
- Clinical Pharmacology & Pharmacometrics, Janssen Research & Development, Beerse, Belgium.
- Bioanalytical Discovery & Development Sciences, Janssen Research & Development, Beerse, Belgium.
- Preclinical Sciences & Translational Safety, Janssen Research & Development, Beerse, Belgium.
Zitieren
APA
Jaiprasart, P., Hellemans, P., Jiao, J. J., Dosne, A. G., De Meulder, M., De Zwart, L., Brees, L., & Zhu, W. (2024). Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1412
Vancouver
Jaiprasart P, Hellemans P, Jiao JJ, Dosne AG, De Meulder M, De Zwart L, et al. Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1412
BibTeX
@article{Jaiprasart2024,
author = {Jaiprasart, Pharavee and Hellemans, Peter and Jiao, Juhui James and Dosne, Anne-Gaëlle and De Meulder, Marc and De Zwart, Loeckie and Brees, Laurane and Zhu, Wei},
title = {Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1412}
}
EUVIMED